Calendar
July 2018
M T W T F S S
« Mar    
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Categories

Newsletter

* required fields
Aglaris Appoints Steven Docksey as CEO
 
 

Stevenage, UK and Madrid, Spain, 1 July 2018Today is a great day for Aglaris. Due to the preparation to take our company to the next stage, there has been a change of relevance for all. Through this e-mail, it is an honor for us to introduce to you the new CEO of the company, Steven Docksey, who will join the management team of Aglaris as of today, July 1. Steven will be working part-time and will also join the Board of Directors.

 
It is a privilege for us to have Steve in Aglaris, given his career path within the world of Bioprocessing. Steve has held senior management positions with world leading companies including: GE Healthcare Life Scienses – Chief Marketing Officer, Millipore Corporation – VP Global Marketing, Millipore Europe – Managing Director, Stedim Biosystems – VP Business Operations. Steve started his career in technology as a research microbiologist and has over 30 years experience in life sciences and healthcare. He has attended senior management programmes at INSEAD business school in Fontainebleau.
 
Steve will help us take Aglaris one step further. This movement does not imply any changes in the strategy that we have maintained during the last years as we are very satisfied with our trajectory and we want to maintain it.
 
 
-ENDS-
 
 
 
CONTACTS
Aglaris Ltd
Dr David Horna
 
Dr Miquel Costa
 
 
 Twitter: @Aglariscell
 
NOTES TO EDITOR
 
About Aglaris Ltd
Aglaris Limited (Aglaris) is developing innovative, automated cell culture platform technologies. Set up in 2014, Aglaris aims to solve the bottleneck in cell and tissue manufacturing, currently inhibiting the wider application of cell-based therapies within regenerative medicine.
 
Aglaris has a clear aspiration to provide an enabling technology platform to make cell therapy a reality. Novel platforms and stem cell approaches are emerging as potentially promising therapies across a wide range of disease areas. This fast-growing global stem cell market is expected to increase threefold and reach £135 billion by 2020[1]. To meet the needs of cell therapies, cell production needs to be more affordable and technically competitive. Aglaris has developed the Facer 1.0 prototype (integrating the Aglaris technology in an automated bioreactor) and a number of ancillary technologies (e.g., microparticles, filtration system, sensor array etc.) which are currently under validation at Aglaris’ headquarters at the Stevenage Bioscience Catalyst (UK) and its laboratory premises at Parque Tecnológico de Madrid (Spain).
 
The experienced management team and board bring a proven track record of clinical and scientific credentials in founding, developing and commercialisation of technologies. Investments in Aglaris to date include grants and venture funding from renowned public and private institutions. For further information, please visit www.aglaris.co.uk.
Aglaris to Present and Attend Upcoming UK Conferences
 
Key conferences include BIA, Phacilitate SIG and Anglo Nordic
 
Stevenage, UK and Madrid, Spain, 25 May 2017 – Aglaris Ltd (Aglaris), an innovative cell culture platform technology company, announces it will be attending and presenting a company overview at the following conferences. Aglaris is focussed on the provision of automated transformative cell culture technologies that address issues in personalised, regenerative and cellular therapies.
 
 
25 May 2017, The Oxford Belfry, Milton Common, Milton Common, OX9 2JW
 
Aglaris to present at the Innovation showcase at the event on 25 May at 14:00.
 
The flagship UK CEO and Investor Forum is hosted at the Oxford Belfry, at Milton Common, Oxford. This invite only forum is attracts C-suite and senior managers in corporate organisations and investors, and known for its peer-to-peer networking, discussions and debates.
 
 
30 & 31 May 2017, Hopetoun House, Queensferry, Edinburgh EH30 9SL
 
Aglaris to present and host meetings.
 
Phacilitate’s inaugural SIG, is a unique and exclusive think tank drawing together the cell and gene therapy sector’s manufacturing decision makers with the ‘do-ers’: namely the bioprocess developers and engineers tasked with sourcing, selecting and implementing automated solutions.
 
 
31 May 2017, 8 Northumberland Ave, London WC2N 5BY
 
Aglaris to present and host meetings. The company presentation is at 14:00 in the Technologies Room.
 
This year’s fourteenth Anglo Nordic conference takes place at the prestigious 8 Northumberland Avenue, just a few steps from Trafalgar Square in central London. The conference provides a platform to meet decision makers at leading and upcoming drug discovery and medtech companies from the Anglo-Nordic regions, international pharmaceuticals and investment firms. Belgium is this year’s guest country.
 
 
-ENDS-
 
 
 
CONTACTS
Aglaris Ltd
Dr David Horna
 
Dr Miquel Costa
 
Investor Relations
Supriya Mathur
 
 Twitter: @Aglariscell
 
NOTES TO EDITOR
 
About Aglaris Ltd
Aglaris Limited (Aglaris) is developing innovative, automated cell culture platform technologies. Set up in 2014, Aglaris aims to solve the bottleneck in cell and tissue manufacturing, currently inhibiting the wider application of cell-based therapies within regenerative medicine.
 
Aglaris has a clear aspiration to provide an enabling technology platform to make cell therapy a reality. Novel platforms and stem cell approaches are emerging as potentially promising therapies across a wide range of disease areas. This fast-growing global stem cell market is expected to increase threefold and reach £135 billion by 2020[1]. To meet the needs of cell therapies, cell production needs to be more affordable and technically competitive. Aglaris has developed the Facer 1.0 prototype (integrating the Aglaris technology in an automated bioreactor) and a number of ancillary technologies (e.g., microparticles, filtration system, sensor array etc.) which are currently under validation at Aglaris’ headquarters at the Stevenage Bioscience Catalyst (UK) and its laboratory premises at Parque Tecnológico de Madrid (Spain).
 
The experienced management team and board bring a proven track record of clinical and scientific credentials in founding, developing and commercialisation of technologies. Investments in Aglaris to date include grants and venture funding from renowned public and private institutions. For further information, please visit www.aglaris.co.uk.

Nothing Found

It seems we cannot find what you are looking for. Perhaps searching can help.